| Name | Title | Contact Details |
|---|
Founded in Los Angeles in 2007, Cinesamples has grown to become an industry leader in the development of top virtual instruments and sample libraries. We are passionate about the sampling process, and you can hear our products in many films, tv shows, and video games.
Chartered in 1901 as Irondale Bank of Irondale, MO, Unico Bank has thrived under the ownership of Leon and Barbara Brinkley for the past 30 years. Now, Unico Bank has 10 locations in Southeast Missouri and Northeast Arkansas to serve your banking needs. We pay competitive rates on deposit accounts and offer great low rates for loans to fit your needs. Visit any of our banking centers to see how Unico Bank is committed to Everyday Excellence.
FM Global is a Rhode Island-based insurance company that specializes in property insurance, risk consulting and loss prevention for businesses.
Bank of George emerged with a new brand celebrating our technological advancements in the digital space – GBank! We are proud of our improved digital banking and mobile apps for both your personal and business accounts. With increased functionality and efficiency, we know you will love the new GBank. And as tech advances, so will we. We will never lose sight of the core values that have made us your chosen community bank as we grow. Our goal is to give our clients the highest level of service and care at all times. When they look back and assess their relationship with our institution, the total of all the interactions along their banking journey with GBank equals Your Best Banking Experience Ever!® But it doesnt stop there. Our goal is always to give our colleagues that same level of service and care.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.